UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 
 
 
 
 
Filed by Registrant  x   Filed by a Party other than the Registrant:  o
 
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
x
Definitive Additional Materials
o
Soliciting Material Pursuant to §240.14a-12
Spark Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
 
 
 
 
 
 
x
 
No fee required.
 
 
o
 
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
 
 
 
 
(1)
 
Title of each class of securities to which transaction applies: 
 
 
(2)
 
Aggregate number of securities to which transaction applies:     
 
 
(3)
 
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):     
 
 
(4)
 
Proposed maximum aggregate value of transaction:     
 
 
(5)
 
Total fee paid:     
 
 
 
 
 
o
 
Fee paid previously with preliminary materials.
 

 
 
 
o
 
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.





 
 
 
 
 
(1
)
 
Amount Previously Paid:     
 
(2
)
 
Form, Schedule or Registration Statement No.:     
 
(3
)
 
Filing Party:     
 
(4
)
 
Date Filed:     





VOTE1.JPG




VOTE2.JPG




Voting items

The Board of Directors recommends you vote
FOR the following proposal:

1. Election of Class II Directors

Nominees

01) Steven M. Altschuler M.D. 02) Lars Ekman M.D., Ph.D.    03) Katherine A. High M.D.


The Board of Directors recommends you vote FOR the following proposal:

2.
To approve, on an advisory basis, the compensation paid to the Company’s named executive officers.

The Board of Directors recommends you vote 1 YEAR for the following proposal:

3.
To recommend, on an advisory basis, the frequency of future stockholder advisory votes on the compensation paid to the Company’s named executive officers.

The Board of Directors recommends you vote FOR the following proposal:

4.
To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017.


NOTE: Such other business as may properly come before the meeting or any adjournment thereof.



Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Onconetix Charts.
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Onconetix Charts.